Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,292.55",
    "chg": 32.95,
    "chgp": "2.62%",
    "dir": 1,
    "prev_price": "1,259.60",
    "mcapval": "107,883.11 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "4.78 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 18.89 vs Industry's 31.53: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3915460",
        "imagepath": "",
        "date": "2026-03-25 09:21:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\" target=\"_blank\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 18.89, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 31.53. This represents a discount of approximately 40%, suggesting the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable in a sector where many stocks command premium multiples due to robust innovation pipelines and steady demand for healthcare products. The discount raises the question of whether the stock’s fundamentals justify this divergence or if it presents a valuation anomaly — ..."
      },
      {
        "title": "Dr Reddys Laboratories Downgraded to Sell Amid Technical and Financial Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-downgraded-to-sell-amid-technical-and-financial-weakness-3909423",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_mojoScore_3909423.png",
        "date": "2026-03-24 08:36:21",
        "description": "Dr Reddys Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 March 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite the company’s strong long-term fundamentals and low debt profile."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Faces Mildly Bearish Momentum Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-mildly-bearish-momentum-amid-technical-shifts-3909187",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_technicaldot_3909187.png",
        "date": "2026-03-24 08:03:32",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment for the pharmaceutical giant as it navigates current price pressures and sector dynamics."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure on 23 Mar 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-low-amid-price-pressure-on-23-mar-2026-3908207",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_priceRelatedfactors_3908207.png",
        "date": "2026-03-23 15:01:03",
        "description": "Dr Reddys Laboratories Ltd experienced a notable intraday decline on 23 Mar 2026, touching a low of Rs 1260.05, reflecting a 2.99% drop from previous levels amid broader market weakness and sectoral pressures."
      },
      {
        "title": "P/E at 19.41 vs Industry's 31.90: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3906712",
        "imagepath": "",
        "date": "2026-03-23 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Industry Premiums</strong></p>\n                <p>The P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 19.41 stands well below the industry average of 31.90, signalling a valuation discount of approximately 39%. This gap suggests that the market is pricing in either a more cautious outlook on the company's earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> remains valued more conservatively. <..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3902447",
        "imagepath": "",
        "date": "2026-03-20 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity market landscape. This membership not only reflects the company’s substantial market capitalisation—currently standing at ₹1,08,350.52 crores, categorising it firmly as a large-cap stock—but also ensures heightened visibility among domestic and international investors. Index inclusion typically results in increased liquidity and trading volumes, as many passive funds and ETFs track the Nifty 50, mandating investment in its components.</p>\n                <p>Dr Reddys’ presence in this benchmark index also signals its role as a bellwether for the Pharmaceuticals & Biotechnology sector, which is a criti..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-3899623",
        "imagepath": "",
        "date": "2026-03-19 09:21:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity landscape. The index, representing the top 50 companies by free-float market capitalisation, serves as a benchmark for institutional investors and mutual funds. Inclusion ensures enhanced liquidity, greater visibility, and often, a more stable investor base. For Dr Reddys, this status affirms its market leadership within the Pharmaceuticals & Biotechnology sector, which is critical given the sector’s evolving dynamics and competitive pressures.</p>\n                <p>With a market capitalisation of ₹1,05,867.42 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its weight in the index. ..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3898159",
        "imagepath": "",
        "date": "2026-03-18 09:21:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a benchmark for institutional investors and passive funds alike. Inclusion ensures that Dr Reddys benefits from consistent inflows from index-tracking funds, which can provide a stabilising effect on its share price during volatile market phases.</p>\n                <p>With a market capitalisation of ₹1,06,965 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its eligibility for index membership. This status also e..."
      },
      {
        "title": "Dr Reddys Laboratories Upgraded to Hold on Technical and Valuation Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-upgraded-to-hold-on-technical-and-valuation-improvements-3895924",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_mojoScore_3895924.png",
        "date": "2026-03-17 08:31:44",
        "description": "Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 16 March 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and quality parameters. Despite recent quarterly setbacks, the company’s long-term fundamentals and evolving market signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 506,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Mar-2026",
      "details": "Intimation of Board meeting date and Trading Window closure",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Considering The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ending On March 31 2026",
      "datetime": "23-Mar-2026",
      "details": "Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 inter alia to consider and approve To consider the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 18.89 vs Industry's 31.53: What the Data Shows for Dr Reddys Laboratories Ltd

2026-03-25 09:21:07

Valuation Picture: Discount to Industry P/E

Dr Reddys Laboratories Ltd trades at a P/E multiple of 18.89, markedly below the Pharmaceuticals & Biotechnology industry average of 31.53. This represents a discount of approximately 40%, suggesting the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable in a sector where many stocks command premium multiples due to robust innovation pipelines and steady demand for healthcare products. The discount raises the question of whether the stock’s fundamentals justify this divergence or if it presents a valuation anomaly — ...

Read full news article

Dr Reddys Laboratories Downgraded to Sell Amid Technical and Financial Weakness

2026-03-24 08:36:21

Dr Reddys Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 March 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite the company’s strong long-term fundamentals and low debt profile.

Read full news article

Dr Reddys Laboratories Ltd Faces Mildly Bearish Momentum Amid Technical Shifts

2026-03-24 08:03:32

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment for the pharmaceutical giant as it navigates current price pressures and sector dynamics.

Read full news article

Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure on 23 Mar 2026

2026-03-23 15:01:03

Dr Reddys Laboratories Ltd experienced a notable intraday decline on 23 Mar 2026, touching a low of Rs 1260.05, reflecting a 2.99% drop from previous levels amid broader market weakness and sectoral pressures.

Read full news article

P/E at 19.41 vs Industry's 31.90: What the Data Shows for Dr Reddys Laboratories Ltd

2026-03-23 09:20:50

Valuation Picture: Discount Amidst Industry Premiums

The P/E ratio of Dr Reddys Laboratories Ltd at 19.41 stands well below the industry average of 31.90, signalling a valuation discount of approximately 39%. This gap suggests that the market is pricing in either a more cautious outlook on the company's earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, yet Dr Reddys Laboratories Ltd remains valued more conservatively. <...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics

2026-03-20 09:20:55

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity market landscape. This membership not only reflects the company’s substantial market capitalisation—currently standing at ₹1,08,350.52 crores, categorising it firmly as a large-cap stock—but also ensures heightened visibility among domestic and international investors. Index inclusion typically results in increased liquidity and trading volumes, as many passive funds and ETFs track the Nifty 50, mandating investment in its components.

Dr Reddys’ presence in this benchmark index also signals its role as a bellwether for the Pharmaceuticals & Biotechnology sector, which is a criti...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Market Signals

2026-03-19 09:21:02

Significance of Nifty 50 Membership

Being part of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity landscape. The index, representing the top 50 companies by free-float market capitalisation, serves as a benchmark for institutional investors and mutual funds. Inclusion ensures enhanced liquidity, greater visibility, and often, a more stable investor base. For Dr Reddys, this status affirms its market leadership within the Pharmaceuticals & Biotechnology sector, which is critical given the sector’s evolving dynamics and competitive pressures.

With a market capitalisation of ₹1,05,867.42 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its weight in the index. ...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics

2026-03-18 09:21:05

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a benchmark for institutional investors and passive funds alike. Inclusion ensures that Dr Reddys benefits from consistent inflows from index-tracking funds, which can provide a stabilising effect on its share price during volatile market phases.

With a market capitalisation of ₹1,06,965 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its eligibility for index membership. This status also e...

Read full news article

Dr Reddys Laboratories Upgraded to Hold on Technical and Valuation Improvements

2026-03-17 08:31:44

Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 16 March 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and quality parameters. Despite recent quarterly setbacks, the company’s long-term fundamentals and evolving market signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News